MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination

Shota Obata; Sumi Hidaka; Mizuki Yamano; Mitsuru Yanai; Kunihiro Ishioka; Shuzo Kobayashi

doi:10.1093/ckj/sfab181

MPO-ANCA-associated vasculitis after the Pfizer/BioNTech SARS-CoV-2 vaccination

Clin Kidney J. 2021 Sep 28;15(2):357-359. doi: 10.1093/ckj/sfab181. eCollection 2022 Feb.

Authors

Shota Obata¹, Sumi Hidaka¹, Mizuki Yamano¹, Mitsuru Yanai², Kunihiro Ishioka¹, Shuzo Kobayashi¹

Affiliations

¹ Kidney Disease and Transplant Center, Shonan Kamakura General Hospital, Japan.
² Department of Pathology, Sapporo Tokushukai Hospital, Japan.

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has demonstrated high efficacy at preventing coronavirus disease 2019 (COVID-19) and a favorable safety profile, however it has also been reported that COVID-19 vaccines may put increase of immune-mediated disease. We herein report a case of MPO-anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis following the mRNA vaccine BNT162b2 (Pfizer/BioNTech) for COVID-19. Although the causal relationship between vaccine and ANCA-associated vasculitis is uncertain, environmental and genetic factors may have set the stage for the development of vasculitis, and the vaccine may have triggered a domino effect.

Keywords: ANCA-associated vasculitis; MPO-ANCA; SARS-CoV-2; focal necrotizing glomerulonephritis; mRNA vaccine.